Targets › CANX
1 program from 1 company in 1 trial: 1 Phase 2; Oncology.
Calcium-binding protein that interacts with newly synthesized monoglucosylated glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. (UniProt, P27824)
Open in Phaseline: the race on CANX, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| NanoEcho | NanoEcho Particle-1 (NEP-1, Ferumoxtran) Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles - iron oxide contrast agent | CANX | Phase 2 | Healthy Volunteers | – |
Healthy Volunteers (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.